COVID-19 住院患者中的肺栓塞。
Pulmonary embolism in hospitalised patients with COVID-19.
机构信息
Dept of Medicine, King's College NHS Foundation Trust, London, UK; Dept Clinical and Experimental Medicine, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.
Dept of Medicine, King's College NHS Foundation Trust, London, UK.
出版信息
Thromb Res. 2020 Nov;195:95-99. doi: 10.1016/j.thromres.2020.07.025. Epub 2020 Jul 10.
BACKGROUND
Coronavirus disease 2019 (COVID-19) is characterised by dyspnoea and abnormal coagulation parameters, including raised D-dimer. Data suggests a high incidence of pulmonary embolism (PE) in ventilated patients with COVID-19.
OBJECTIVES
To determine the incidence of PE in hospitalised patients with COVID-19 and the diagnostic yield of Computer Tomography Pulmonary Angiography (CTPA) for PE. We also examined the utility of D-dimer and conventional pre-test probability for diagnosis of PE in COVID-19.
PATIENTS/METHODS: Retrospective review of single-centre data of all CTPA studies in patients with suspected or confirmed COVID-19 identified from Electronic Patient Records (EPR).
RESULTS
There were 1477 patients admitted with COVID-19 and 214 CTPA scans performed, of which n = 180 (84%) were requested outside of critical care. The diagnostic yield for PE was 37%. The overall proportion of PE in patients with COVID-19 was 5.4%. The proportions with Wells score of ≥4 ('PE likely') was 33/134 (25%) without PE vs 20/80 (25%) with PE (P = 0.951). The median National Early Warning-2 (NEWS2) score (illness severity) was 5 (interquartile range [IQR] 3-9) in PE group vs 4 (IQR 2-7) in those without PE (P = 0.133). D-dimer was higher in PE (median 8000 ng/mL; IQR 4665-8000 ng/mL) than non-PE (2060 ng/mL, IQR 1210-4410 ng/mL, P < 0.001). In the 'low probability' group, D-dimer was higher (P < 0.001) in those with PE but had a limited role in excluding PE.
CONCLUSIONS
Even outside of the critical care environment, PE in hospitalised patients with COVID-19 is common. Of note, approaching half of PE events were diagnosed on hospital admission. More data are needed to identify an optimal diagnostic pathway in patients with COVID-19. Randomised controlled trials of intensified thromboprophylaxis are urgently needed.
背景
2019 年冠状病毒病(COVID-19)的特征是呼吸困难和异常的凝血参数,包括升高的 D-二聚体。数据表明,COVID-19 患者中呼吸机通气的患者肺栓塞(PE)发病率很高。
目的
确定住院 COVID-19 患者中 PE 的发生率和计算机断层肺动脉造影(CTPA)对 PE 的诊断效果。我们还检查了 D-二聚体和常规预测试验概率在 COVID-19 中的诊断 PE 的效用。
患者/方法:回顾性分析从电子病历(EPR)中确定的疑似或确诊 COVID-19 患者的单中心 CTPA 研究数据。
结果
有 1477 名 COVID-19 患者入院,共进行了 214 次 CTPA 扫描,其中 n=180(84%)是在重症监护病房外要求进行的。PE 的诊断率为 37%。COVID-19 患者中 PE 的总体比例为 5.4%。具有≥4 分(“PE 可能性大”)的 Wells 评分的患者中,无 PE 的比例为 33/134(25%),而有 PE 的比例为 20/80(25%)(P=0.951)。PE 组的中位国家早期预警-2(NEWS2)评分(疾病严重程度)为 5(四分位距[IQR]3-9),无 PE 组为 4(IQR 2-7)(P=0.133)。PE 组的 D-二聚体更高(中位数 8000ng/mL;IQR 4665-8000ng/mL),而非 PE 组(2060ng/mL,IQR 1210-4410ng/mL,P<0.001)。在“低概率”组中,PE 患者的 D-二聚体更高(P<0.001),但在排除 PE 方面作用有限。
结论
即使在重症监护环境之外,住院 COVID-19 患者中也常见 PE。值得注意的是,近一半的 PE 事件是在入院时诊断出的。需要更多的数据来确定 COVID-19 患者的最佳诊断途径。急需进行强化抗栓治疗的随机对照试验。